LivaNova (NASDAQ:LIVN) Price Target Raised to $70.00

LivaNova (NASDAQ:LIVN) had its price target boosted by equities research analysts at Robert W. Baird from $63.00 to $70.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s target price indicates a potential upside of 23.63% from the company’s current price.

Other research analysts have also recently issued reports about the stock. The Goldman Sachs Group set a $55.00 price target on shares of LivaNova and gave the stock a “neutral” rating in a report on Wednesday, October 1st. Mizuho boosted their price objective on shares of LivaNova from $65.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday. Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LivaNova in a research report on Wednesday, October 8th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of LivaNova in a report on Wednesday, September 3rd. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, LivaNova currently has an average rating of “Moderate Buy” and an average price target of $62.43.

LivaNova Trading Up 7.5%

Shares of NASDAQ LIVN opened at $56.62 on Thursday. LivaNova has a fifty-two week low of $32.48 and a fifty-two week high of $58.91. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. The company has a market cap of $3.09 billion, a price-to-earnings ratio of -14.56 and a beta of 1.00. The business’s 50 day moving average price is $53.82 and its 200-day moving average price is $48.68.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.91 by $0.20. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The company had revenue of $357.80 million during the quarter, compared to analysts’ expectations of $342.32 million. During the same quarter in the previous year, the business earned $0.90 EPS. LivaNova’s revenue was up 12.5% compared to the same quarter last year. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. On average, sell-side analysts expect that LivaNova will post 2.85 earnings per share for the current year.

Institutional Investors Weigh In On LivaNova

A number of hedge funds have recently made changes to their positions in the stock. First Trust Advisors LP boosted its position in LivaNova by 23.5% during the third quarter. First Trust Advisors LP now owns 7,402 shares of the company’s stock valued at $388,000 after purchasing an additional 1,410 shares in the last quarter. Pitcairn Co. purchased a new stake in shares of LivaNova during the third quarter valued at about $342,000. Dimensional Fund Advisors LP boosted its holdings in shares of LivaNova by 6.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,721,173 shares of the company’s stock valued at $90,154,000 after buying an additional 106,889 shares in the last quarter. Rock Point Advisors LLC bought a new stake in shares of LivaNova in the 3rd quarter valued at about $3,066,000. Finally, American Century Companies Inc. grew its position in shares of LivaNova by 31.8% in the 3rd quarter. American Century Companies Inc. now owns 726,950 shares of the company’s stock worth $38,078,000 after buying an additional 175,570 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.